A clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.

Avalanche develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat ophthalmologic disorders.

Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases.

Vical is focused on the development of pharmaceutical product candidates based on its patented gene delivery technology.

Trubion Pharmaceuticals is engaged in the research and development of novel medicines to treat human diseases such as rheumatoid arthritis and non-Hodgkin Lymphoma.

Syntonix Pharmaceuticals is developing next generation biopharmaceuticals that enable better treatment options for patients with devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders.